Oklo Inc.

OKLO · NYSE

$41.67▼ -2.97%

$1.28 today

Mkt cap $6.41B
P/E 0.0
Day $40.77 – $42.80

Confidence

High conviction

The read

OKLO missed EPS estimates as commercialization progress remained ahead of financial proof

Oklo reported a $0.28 loss per share for the quarter ended June 30, versus a $0.17 estimate, a 64.7% miss. The payload provides no forward guidance or post-earnings news. Shares rose 2.97% to $46.47 on August 13 but remained below the 50-day and 200-day moving averages, while funding needs and continued losses remained explicit risks.

Confidence note: Reported EPS and price data were available, but forward guidance, event-window returns, and post-earnings news were unavailable.

What happened

Earnings print

Reported EPS was -$0.28 versus -$0.17 estimated, an EPS miss of $0.11 or 64.7%.

Guidance

Forward guidance was not provided in the payload; guidance tone is unknown.

Price reaction

Event-day and subsequent reaction percentages were unavailable; the stock rose 2.97% to $46.47 on August 13, with 8.21 million shares traded.

Street narrative

No post-earnings news was provided; the stated narrative was commercialization progress ahead of financial results, with potential funding needs before meaningful revenue.

So what

What changed

Reported EPS was -$0.28, $0.11 below estimate, while meaningful revenue remained distant.

What the market is pricing

The August 13 gain to $46.47 suggests resilience, but trading below the 50-day and 200-day averages signals skepticism.

Fundamental takeaway

Keep a cautious bias; upgrade only after a commercialization update reduces funding risk within 30-90 days.

Next 30–90 days

Bull

16%

Commercialization progress could support the technology narrative despite the reported loss and absent meaningful revenue.

A commercialization progress update provides concrete evidence of reactor-plan advancement within 30-90 days.
The stock moves above its $54.72 50-day moving average and sustains that position.

Base

35%

The stock consolidates while investors weigh technical progress against the -$0.28 EPS result and limited financial proof.

No new funding warning appears, while commercialization progress remains the stated catalyst.
The stock remains above its $42.76 20-day moving average but below the $54.72 50-day average.

Bear

49%

The EPS miss and distant revenue could regain control if commercialization requires more capital or losses continue.

Management identifies additional funding as necessary before meaningful revenue arrives.
Shares fall below the $42.76 20-day moving average while remaining below the $54.72 50-day average.

What to do

If you hold it

Hold unless next-quarter revenue misses guidance materially or customer concentration risk worsens.

If you're watching

Add only if next-quarter guidance is reiterated or raised; avoid if guidance is cut or geopolitical risk escalates.

Add to Watchlist

Commercialization progress update within the next 30-90 days.
Any disclosure that additional funding is needed before meaningful revenue arrives.
Price relative to the $42.76 20-day and $54.72 50-day moving averages.
Whether losses continue to weaken the financial case for reactor plans.